Inovio Pharmaceuticals, Inc. (INO)
Evaluation: Based on all recent filings, financial statements, and news.
See full evaluationAsk a question about Inovio Pharmaceuticals, Inc. (INO)
Go deeper and ask any question about INO
Company Performance
Current Price
as of Sep 13, 2024$6.81
P/E Ratio
N/A
Market Cap
$176.82M
Description
Inovio Pharmaceuticals, Inc. engages in the provision of designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases associated with human papillomavirus. Its product pipeline includes VGX-3100, INO-3107, INO-5410, INO-4800, and PENNVAX-GP. The company was founded by David B. Weiner on June 29, 1983 and is headquartered in Plymouth Meeting, PA.
Metrics
Overview
- HQPlymouth Meeting, PA
- SectorHealth Technology
- IndustryPharmaceuticals: Major
- TickerINO
- Price$6.81+2.71%
Trading Information
- Market Cap$176.82M
- Float99.15%
- Average Daily Volume (1m)249,609
- Average Daily Volume (3m)367,830
- EPS-$5.11
Company
- Revenue$0.59M
- Rev Growth (1yr)-55.41%
- Net Income-$32.24M
- Gross Margin-722.36%
- EBITDA Margin-32,123.50%
- EBITDA-$32.37M
- EV$122.32M
- EV/Revenue206.67
- P/EN/A
- P/S312.94
Documents
SEC Filings
Earnings Calls